Pharmaceutical Executive Digest:
Having trouble viewing this e-mail? Click here.
Pharmaceutical Executive Europe  E-News
 
 
 
 
 
 

You can now follow us on Twitter at Twitter.com/pharmexecdigi
 
Survey
We asked 40 pharma leaders, who should be driving universal anticounterfeiting solutions?

Pharma 48%
Regulators 43%
Vendors 9%

Talk to us:
editor@pharmexeceurope.com

Advertise with us: jgray@advanstar.com

22 May, 2012
In this Issue
Pharm Exec 50: Growth from the Bottom Up
This year's Pharm Exec 50 shows an industry whose growth has slowed to a crawl in the face of patent expirations, aggressive payers and a tough environment for approvals. Read more...
Value-Based Pricing: Too High a Cost for UK Pharma?
The UK is set to follow Germany to the ill-defined destination of value-based pricing. Paul Healy of the Stockholm Network explains his concerns. More...
Pharma and Biotech Deals: Outlook Uncertain for 2012
With the pharma stock market falling out of favour, what will 2012 bring in terms of mergers and acquisitions? Peter Young presents highlights from a recent Strategic, M&A and Financial Trends report. More...
EU Responds to Troubled Medical Devices Sector
Following the recent scandal surrounding certain breast implants, no pharmaceutical executive should ignore what happens in the medical devices sector. Reflector reports on new procedures in the EU. More...
Product Profile
NNIT
GxP Cloud now with SaaS
With validated GxP applications ready as SaaS in NNIT's GxP Cloud you can save deployment and validation costs as well as time. Read more
Sciformix
Establishing Case Quality Metrics - defining and using quality metrics for adverse events case processing. Read more

Event Profile
Global Publication Planning & Clinical Trial Registries Forum
Strategies for Effective and Compliant Data Dissemination and Coordination
11-12 June 2012
Amsterdam, Netherlands
The relationship between journal publications and trial databases is essential for full disclosure of clinical results information to the public. At the Global Publication Planning and Clinical Trial Registries Forum. Read more
Also in this issue…
Europe Gets Serious About Geriatric Trials
EMA Toughens up on Transparency
Cheap Versus Expensive